! " " # $$# %%& ' $(! % $ ) * +, + *



Similar documents
E UROPEAN CURRICULUM VITAE FORMAT

Best of San Antonio Breast Cancer Symposium

Breast Cancer. Progress and Controversies. Hotel Royal Continental Via Partenope, 38 Napoli

Curriculum Vitae of Luca Gianni

Lo studio TBCRC-023: Commento sulla metodologia

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

16.30 Kaposi s Sarcoma (KS): an interesting model for studying clinico-pathological relationship in tumorigenesis events

Mediterranean School of Oncology

ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico

Mediterranean School of Oncology

One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.

SAMO FoROMe Post-ESMO 2013 Breast Cancer

The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania

How To Contact Cognome Nome

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

in Breast Cancer 4 International Meeting on New Drugs ROME, NOVEMBER 12-13, 2015 Regina Elena National Cancer Institute Bastianelli Congress Centre

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

Cytotoxic Therapy in Metastatic Breast Cancer

Overall teaching planning and Istitutional tasks Antonio Cuneo (Hematology), Giovanni Lanza (Pathology)

Advances in Biology and Treatment of Malignant Brain Gliomas

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials

DETERMINATION OF HER2 STATUS IN BREAST CANCER PATIENTS BY TWO METHODS: REAL-TIME QUANTITATIVE PCR (QPCR) AND IMMUNOENZIMATIC ASSAY (EIA)

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Come è cambiata la storia naturale della malattia

Sezione di Oncologia. [Workshop] LEARNING at the LEANING tower Pisa Colorectal Cancer 2015

Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies

Mediterranean School of Oncology

Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France September 2008

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

Europass Curriculum Vitae

San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 10 14, 2013

Molecular markers and clinical trial design parallels between oncology and rare diseases?

Cellular, Molecular, and Biochemical Targets in Breast Cancer

Avastin in breast cancer: Summary of clinical data

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

- Pisa, Italy. Azienda Ospedaliero-Universitaria Di Pisa - Ospedale S. Chiara 1/6. General Information

Male Breast Cancer Edward Yu, MD PhD, FRCPC. Department of Oncology, Western University, London, Ontario, Canada

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Università degli Studi di Milano Bicocca Monza

Seconda linea di trattamento

Male breast cancer - Wikipedia, the free encyclopedia

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015

Proportion of patients with invasive breast cancer in whom ER, PR and/or

Cambia l algoritmo terapeutico

Nuevas tecnologías basadas en biomarcadores para oncología

Dal germinale al somatico nella identificazione di tumori ereditari

New Treatment Options for Breast Cancer

Mechanism Of Action of Palbociclib & PFS Benefit

Positività per HER-2 nei carcinomi subcentimetrici

Neoadjuvant (Primary) Systemic Therapy

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Effect of Chemotherapy for Luminal A Breast Cancer

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Future Oncology: Technology, Products, Market and Service Opportunities

New Approval Mechanism for Breast Cancer using pathologic Complete Response

Management of ER+/HER2- Breast Cancer: New Options, New Insights, Coming Agents

Houston Cancer Institute

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Hormonal treatment of metastatic ER+/HER2- breast cancer. Antonio Frassoldati Oncologia Clinica Ferrara

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

SYNOPSIS PROTOCOL NEOPAL

Provincia di Foggia Comune di Foggia

ESMO 2014 Summary Breast Cancer

Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi - Bologna, Italy

Laura Biganzoli Oncologia Medica Nuovo Ospedale di Prato Istituto Toscano Tumori

Transcription:

! " " # $$# %%& ' $(! % $ ) * +, + * -,,! " # $ # " # # # % % & # # '! # % % # ( ) # * + % % % % # % ", # #! % # % - # %! % +,,, +,,! " # $ # " # # # % + '! '! % & # #! / # # & %,,,, *,,! % & / 0 1& # % # # % % & # # #! # % %! #,,,, $ 2 & 3 4& # % # # % # & # # #! # % %! #,,,,

# # # % & # # # 5 ( & % + % " # & 6! #!! / % / / /! / / 7! # +,, + / 0 1 &" & # %! # # % # % & # # #! # #!! % - - 8 9 : 1: 9 ; 9 9 3 1: 9 ; 9 8 #!! ( % )! 8& # 1 $ & & # # % & % 8 9 ; 1: 9 9 < 8 #!! ( % )! & 8& # 1 # % 8=! %! # % 8 ; > >? : 9 9 3 8 #!! ) % / ( % )! & 8& # 1 % / % % % / 8=! %! 6! % / / 86 6! # # 8 ; > > : ; > >? 8 #!! 6 ) @ A$ 8& # 1 * / % % 8=! %! *! 86 # #!! #

2 - * 6 ( 6 6 ( 3 $#! " *" $#! ( " " $# # ( " " $#! ( " " $#! 6 * $# # 6 * $&$ B $" *& C $ $D & " &! & PUBBLICAZIONI O ABSTRACT $" *& C )6 2 6 6 " )$ + $" $" 2 C C ( )&$+ $D 6 " " " & )*&" *$ " )$" &" *$ " " *" 2 & $" 6 " C " &$ &E " )= ( $ $D 6 2 6 6 " + " * $" F $6 G " &" G &" 1) Primary systemic therapy in breast cancer: novel molecular marker concepts Generali D, Berruti A, Cappelletti MR, Forti M, Zanotti L, MIlani M, Ardine M, Strina C, Aguggini S, Gussago F, Zanoni V, Allevi G, Dogliotti L, Fox SB, Harris AL, Bottini A Accepted to J Natl Cancer Inst Monogr2013 2) Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal estrogen and/or progesterone receptor-positive breast cancer Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, Bottini A, Berruti A, Generali D Br J Cancer 2013 Apr 30;108(8) 3) Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer Daniele Generali, William F Symmans, Maria Rosa Cappelletti, Alfredo Berruti Stephen B Fox Accepted J Nat Cancer Inst-2011 4) Gene expression profiling in breast cancer: a clinical perspective Arpino G, Generali D, Sapino A, Lucia del M, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti MR, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L Breast 2013 Apr;22(2):109-20

5) Pharmacogenetics of capecitabine-based treatment in advanced breast cancer patients Maria Rosa Cappelletti, Chiara Foroni, Mara Maldotti, Daniele Andreis, Letizia Bazzola, Carla Strina, Piera Bertoglio, Manuela Milani, Alberto Bottini, Daniele Generali XIII Congresso Nazionale Associazione Italiana Oncologia Medica AIOM 5-7 Novembre 2011, Bologna 6) Proof of the anti-tumour effect of zoledronic acid (za) in naive bone-only metastatic and locally advanced breast cancer (LABC): results from the "biological window therapy Chiara Foroni, Daniele Andreis, Mara Maldotti, Carla Cortellazzi, Maria Rosa Cappelletti, Ermenegilda Boni, Daniele Santini, Alfredo Berruti, Giovanna Damia, Alberto Bottini, Daniele Generali XIII Congresso Nazionale Associazione Italiana Oncologia Medica AIOM 5-7 Novembre 2011, Bologna San Antonio Breast Cancer Symposium 6-10 Dicembre 2011 7) Newsletter Diatech Pharmacogenetics: Farmacogenetica e carcinoma mammario trattato con Fluoropirimidine Maria Rosa Cappelletti, Daniele Generali, Chiara Foroni, Daniele Andreis, Mara Maldotti Dicembre 2011 8) Safety and activity of non-pegylated liposomal doxorubicin (npld) combined with oral metronomic cyclophosphamide (mc) as preoperative treatment for locally advanced breast cancer (BC) patients (pts) Daniele Andreis, Daniele Giulio Generali, Chiara Foroni, Letizia Bazzola, Maria Rosa Cappelletti, Vanessa Zanoni, Manuela Milani, Carla Strina, Giovanni Allevi, Sergio Aguggini, Ermenegilda Boni, Roberto Giardini, Ramona Bertoni, Alberto Bottini 2012 ASCO Annual Meeting June 1-5, 2012 9) Genomic predictive factors identifying toxicity in an ACTIVE non-pegylated liposomal doxorubicin (npld) -based treatment FOR locally advanced breast cancer (BC) Maria Rosa Cappelletti, Daniele Andreis, Vanessa Zanoni, Letizia Bazzola, Carla Strina, Manuela Milani, Morena Ferrari, Chiara Foroni, Alberto Bottini, Daniele Generali AIOM 27-29 Ottobre 2012, Roma 10) Prospective study of positron emission tomography for evaluation of the activity of trastuzumab in HER2 positive patients with locally advanced breast tumors Carla Strina, Chiara Foroni, Daniele Andreis, Vanessa Zanoni, Maria Rosa Cappelletti, Letizia Bazzola, Manuela Milani, Ermenegilda Boni, Giovanni Allevi, Alberto Bottini, Francesco Ferrozzi, Daniele Generali AIOM 27-29 Ottobre 2012, Roma 11) Neoadjuvant treatment approach: the Rosetta stone for breast cancer? Daniele Generali, Mara Ardine, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Laura Zanotti, Michela Forti, Francesca Bedussi, Mario Martinotti, Vito Amoroso, Sandra Sigala, Edda Simoncini, Alfredo Berruti, Alberto Bottini JNCI Monograph 2013

12) Tumor metabolism/autophagy and effect of trastuzumab on her2+ breast carcinoma in patients treated with pre-operative chemotherapy: results of a prospective study Michael I Koukourakis, Alexanda Giatromanolaki, Alberto Bottini, Maria Rosa Cappelletti, Laura Zanotti, Giovanni Allevi, Carla Strina, Mara Ardine, Manuela Milani, Giulia Brugnoli, Mario Martinotti, Giuseppina Ferrero, Ramona Bertoni, Francesco Ferrozzi, Adrian L Harris, Daniele Generali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

- 7 % K / 7? < & 3 3 0 1: 9 9 9 / % 7! #! # % % #! # '! # 6 % % ; > < 19 4 $ * $# # : 0 1; ; 1: 9 ; 4